Clover Biopharmaceuticals, Ltd. (2197.HK) HKSE
Currency In HKD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In HKD
Address
No. 758 West Nanjing Road
Shanghai, SH 200040
China
Phone
86 28 8533 6966
Sector
Healthcare
Industry
Biotechnology
Employees
257
First IPO Date
November 05, 2021
| Name | Title | Pay | Year Born |
| Joshua G. Liang | Chief Executive Officer & Executive Director | 2.27M | 1993 |
| Peng Liang | Founder, Chief Scientific Officer & Chairman of the Board | 4.45M | 1961 |
| Berry Michael | Chief Technical Operation Officer | 0 | 1966 |
| Tracy Wang | Senior Vice President of Head of Regulatory Affairs, China | 0 | N/A |
| Nicolas Burdin | Global Head of R&D | 0 | N/A |
| Igor Smolenov | Executive Vice President of Global Clinical Development Vaccines | 0 | N/A |
| Nicholas Jackson | President of Global R&D and Alliances | 0 | 1971 |
| Htay Htay Han MBBS | Chief Medical Officer of Vaccine | 0 | 1969 |
| Yang Li | Chief Technology Officer | 0 | N/A |
| LiongHo Chua | President of Greater China | 0 | 1964 |
Clover Biopharmaceuticals, Ltd. is a biotechnology enterprise focused on discovering, developing, and commercializing innovative vaccines and biological therapies. Their efforts target infectious diseases, various cancers, and autoimmune conditions. The company's pipeline features several key candidates: SCB-2019 (CpG 1018/Alum): A COVID-19 vaccine candidate currently advancing through Phase II/III clinical trials. SCB-313: A trimeric fusion protein aimed at treating severe intracavitary malignancies, including malignant ascites, malignant pleural effusions, and peritoneal carcinomatosis, addressing a significant global medical need. SCB-808: Undergoing pivotal Phase III clinical trials for the management of rheumatic disorders. SCB-420: An aflibercept biosimilar in preclinical development for ophthalmologic conditions like wet age-related macular degeneration. SCB-219: A novel TPOR agonist in preclinical stages for the treatment of chemotherapy-induced thrombocytopenia and immune thrombocytopenic purpura. Clover also holds a collaboration and supply agreement with Dynavax, which provides its CpG 1018 adjuvant for use in preclinical studies. The company was established in 2007 and is based in Shanghai, China.